Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Products, net	$ 309,322	$ 207,774	$ 779,805	$ 607,836
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Collaboration	$ 22,495	$ 22,495	$ 66,750	$ 66,750
Total revenues	331,817	230,269	846,555	674,586
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	37,026	39,952	106,167	109,190
Research and development	194,301	216,707	681,870	663,286
Selling, general and administrative	120,893	104,787	350,171	330,943
Amortization of in-licensed rights	439	178	796	535
Total cost and expenses	352,659	361,624	1,139,004	1,103,954
Operating loss	(20,842)	(131,355)	(292,449)	(429,368)
Other loss, net:
Gain from sale of Priority Review Voucher	0	0	102,000	0
Loss on debt extinguishment	0	(125,441)	(387,329)	(125,441)
Other income (expense), net	(12,332)	378	17,309	(33,848)
Total other (loss), net	(12,332)	(125,063)	(268,020)	(159,289)
Loss before income tax expense (benefit)	(33,174)	(256,418)	(560,469)	(588,657)
Income tax expense (benefit)	7,763	1,320	21,163	5,587
Net loss	(40,937)	(257,738)	(581,632)	(594,244)
Other comprehensive income (loss):
Unrealized gains (losses) on investments, net of tax	417	(720)	1,026	(3,185)
Total other comprehensive income (loss)	417	(720)	1,026	(3,185)
Comprehensive loss	$ (40,520)	$ (258,458)	$ (580,606)	$ (597,429)
Net loss per share - basic	$ (0.46)	$ (2.94)	$ (6.56)	$ (6.79)
Net loss per share - diluted	$ (0.46)	$ (2.94)	$ (6.56)	$ (6.79)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	88,889	87,628	88,609	87,465
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	88,889	87,628	88,609	87,465